Repare Therapeutics Inc. reported its financial results for the third quarter of 2025, revealing a significant shift in its revenue and operational strategy. The company generated $11.6 million in revenue during the three months ended September 30, 2025, compared to no revenue in the same period last year. This increase is attributed to the recognition of revenue from a collaboration agreement with Debiopharm, which included a $10 million upfront payment and additional payments related to the transfer of clinical trial materials. For the nine months ended September 30, 2025, total revenue was $11.9 million, a decrease from $53.5 million in the prior year, primarily due to the termination of the Roche collaboration agreement, which accounted for a significant portion of the previous year's revenue.
The company's operating expenses for the third quarter of 2025 were $13.9 million, down from $36.4 million in the same quarter of 2024. This reduction was driven by a $20.9 million decrease in research and development expenses, which fell to $7.5 million from $28.4 million year-over-year. The decrease in R&D spending was largely due to cost-saving measures implemented as part of a strategic re-prioritization of the company's clinical portfolio, including the termination of several clinical trials. General and administrative expenses also decreased to $4.5 million from $6.4 million, reflecting lower personnel-related costs and reduced public company-related fees.
Repare's net income for the third quarter was $3.3 million, a notable improvement from a net loss of $34.4 million in the same quarter of 2024. The company reported a net loss of $43.5 million for the nine months ended September 30, 2025, compared to a loss of $56 million for the same period in 2024. The improved financial performance is attributed to the gains from the sale of technology and other assets, as well as the termination of collaboration agreements, which provided additional income.
In terms of strategic developments, Repare announced a definitive arrangement agreement with XenoTherapeutics, Inc. on November 14, 2025, under which Xeno will acquire all outstanding common shares of Repare. The transaction is expected to close in the first quarter of 2026, subject to shareholder and court approvals. This acquisition is part of Repare's ongoing efforts to streamline operations and focus on its clinical-stage oncology programs, particularly RP-3467 and RP-1664, while reducing its workforce by approximately 75% by the end of 2025.
Looking ahead, Repare anticipates that its cash and cash equivalents, along with marketable securities totaling $112.6 million as of September 30, 2025, will be sufficient to fund its operations through 2027. However, the company acknowledges the inherent uncertainties in clinical development and the need for additional capital to support its ongoing projects. The management remains focused on advancing its clinical programs while navigating the complexities of the current economic landscape and potential market conditions.
About Repare Therapeutics Inc.
Repare Therapeutics is a clinical-stage biotech specializing in precision oncology through synthetic lethality. Using its proprietary SNIPRx platform, it develops targeted small-molecule therapeutics for genetically-defined cancers, focusing on DNA repair and genomic instability. Its portfolio includes candidates like RP-3467 and RP-1664, targeting DNA polymerase theta and PLK4, respectively. The company collaborates with industry partners, relies on third-party manufacturing, and aims to advance cancer treatments with a competitive edge in targeted therapy development.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.